BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35654076)

  • 1. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial.
    Ortiz-Romero PL; Maroñas Jiménez L; Muniesa C; Estrach T; Servitje O; Fernández-de-Misa R; Gallardo F; Sanmartín O; Riveiro-Falkenbach E; García-Díaz N; Vega R; Lora D; Postigo C; Jiménez B; Sánchez-Beato M; Pedro Vaqué J; Rodríguez Peralto JL; de la Cámara AG; de la Cruz J; Piris Pinilla MÁ
    Lancet Haematol; 2022 Jun; 9(6):e425-e433. PubMed ID: 35654076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
    Tacastacas JD; Chan DV; Carlson S; Gerson SL; Dowlati A; Fu P; Lu K; Groft S; Rosenjack J; Honda K; McCormick TS; Cooper KD
    JAMA Dermatol; 2017 May; 153(5):413-420. PubMed ID: 28199478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term control of mycosis fungoides of the hands with topical bexarotene.
    Lain T; Talpur R; Duvic M
    Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides.
    Demierre MF; Vachon L; Ho V; Sutton L; Cato A; Leyland-Jones B
    Arch Dermatol; 2003 May; 139(5):624-8. PubMed ID: 12756099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis.
    Phan K; Ramachandran V; Fassihi H; Sebaratnam DF
    JAMA Dermatol; 2019 Mar; 155(3):335-341. PubMed ID: 30698622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
    Kim EJ; Mangold AR; DeSimone JA; Wong HK; Seminario-Vidal L; Guitart J; Appel J; Geskin L; Lain E; Korman NJ; Zeitouni N; Nikbakht N; Dawes K; Akilov O; Carter J; Shinohara M; Kuzel TM; Piette W; Bhatia N; Musiek A; Pariser D; Kim YH; Elston D; Boh E; Duvic M; Huen A; Pacheco T; Zwerner JP; Lee ST; Girardi M; Querfeld C; Bohjanen K; Olsen E; Wood GS; Rumage A; Donini O; Haulenbeek A; Schaber CJ; Straube R; Pullion C; Rook AH; Poligone B
    JAMA Dermatol; 2022 Sep; 158(9):1031-1039. PubMed ID: 35857290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
    Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; Chan DV; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD
    Arch Dermatol; 2012 May; 148(5):613-20. PubMed ID: 22250189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.
    Vieyra-Garcia P; Fink-Puches R; Porkert S; Lang R; Pöchlauer S; Ratzinger G; Tanew A; Selhofer S; Paul-Gunther S; Hofer A; Gruber-Wackernagel A; Legat F; Patra V; Quehenberger F; Cerroni L; Clark R; Wolf P
    JAMA Dermatol; 2019 May; 155(5):538-547. PubMed ID: 30892603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
    Lessin SR; Duvic M; Guitart J; Pandya AG; Strober BE; Olsen EA; Hull CM; Knobler EH; Rook AH; Kim EJ; Naylor MF; Adelson DM; Kimball AB; Wood GS; Sundram U; Wu H; Kim YH
    JAMA Dermatol; 2013 Jan; 149(1):25-32. PubMed ID: 23069814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
    Duvic M; Sherman ML; Wood GS; Kuzel TM; Olsen E; Foss F; Laliberté RJ; Ryan JL; Zonno K; Rook AH
    J Am Acad Dermatol; 2006 Nov; 55(5):807-13. PubMed ID: 17052486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for mycosis fungoides.
    Weberschock T; Strametz R; Lorenz M; Röllig C; Bunch C; Bauer A; Schmitt J
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008946. PubMed ID: 22972128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
    de Quatrebarbes J; Estève E; Bagot M; Bernard P; Beylot-Barry M; Delaunay M; D'Incan M; Souteyrand P; Vaillant L; Cordel N; Courville P; Joly P
    Arch Dermatol; 2005 Sep; 141(9):1117-20. PubMed ID: 16172308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study.
    Apisarnthanarax N; Talpur R; Ward S; Ni X; Kim HW; Duvic M
    J Am Acad Dermatol; 2004 Apr; 50(4):600-7. PubMed ID: 15034511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical tacrolimus for atopic dermatitis.
    Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
    Kim YH; Martinez G; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Feb; 139(2):165-73. PubMed ID: 12588222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical clobetasol propionate treatment and cutaneous adverse effects in patients with early-stage mycosis fungoides: an observational study.
    Geller S; Myskowski PL
    Cutis; 2020 May; 105(5):E27-E32. PubMed ID: 32603400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future role of topical pimecrolimus in early stage mycosis fungoides?
    Scarisbrick JJ
    Lancet Haematol; 2022 Jun; 9(6):e389-e391. PubMed ID: 35654069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.